Increased circulating RANTES in type 2 diabetes.
OBJECTIVE
The pro-atherogenic role of RANTES, a chemokine expressing pleiotropic activities, in the course of type 2 diabetes-related atherosclerosis has been well documented. However, it is not known which of the diabetes-related factors primarily influence serum RANTES levels in patients with type 2 diabetes. Our aim was to investigate relationships between several factors known to be related to an increased risk of atherosclerosis and serum RANTES levels in type 2 diabetic patients.


METHODS
A total of 168 subjects were examined, which included 138 patients with type 2 diabetes and 30 non-diabetic controls. Measurements of venous, fasting, plasma glucose, HbA1c, lipid profile, 1,5-anhydro-D-glucitol (1,5-AG) plasma levels, homocysteine and the fasting, serum C-peptide levels were performed. Serum concentrations of RANTES were assayed using BD(TM) Cytometric Bead Array tests. Peripheral insulin resistance was expressed according to a new index defined by Ohkura et al.


RESULTS
RANTES levels in type 2 diabetic patients correlated with 1,5-AG, fasting glycaemia, HbA1c and the Ohkura index. Multivariate regression analysis was performed taking into consideration several factors related to the inflammatory process and atherosclerosis, namely the patient's age, diabetes duration, waist circumference, 1,5-AG, HbA1c, lipid profile parameters, serum homocysteine levels and Ohkura index, as independent variables potentially influencing serum RANTES levels in type 2 diabetic patients. It is shown that RANTES concentrations in the serum is primarily dependent upon 1,5-AG plasma levels.


CONCLUSIONS
Our results suggest that increased serum levels of RANTES in type 2 diabetic patients are closely related to postprandial (acute) hyperglycaemia.
Department of Pharmacology Poznan University of Medical Sciences, Rokietnicka 5a, 60-805 Poznań, Poland.
Marzena
M
Dworacka
Poznan Specialist Centre of Medical Care, Diabetology Out-patient Clinic, Al. Solidarności 36, 69-61-696 Poznan, Poland.
Ewa
E
Krzyżagórska
Department of Pharmacology Marat Ospanov University of Medical Sciences, Mareshev str. 68, Aktobe, 030019 Kazakhstan.
Saule
S
Iskakova
Department of Oncology Marat Ospanov University of Medical Sciences, Mareshev str. 68, Aktobe, 030019 Kazakhstan.
Yerbol
Y
Bekmukhambetov
Department of Oncology Marat Ospanov University of Medical Sciences, Mareshev str. 68, Aktobe, 030019 Kazakhstan.
Olzhas
O
Urazayev
Department of Clinical Immunology Poznan University of Medical Sciences, Rokietnicka 5d, 60-805 Poznań, Poland.
Grzegorz
G
Dworacki
D001786:Blood Glucose / Q000378:metabolism; D016022:Case-Control Studies; D018946:Chemokine CCL5 / Q000097:blood*; D003847:Deoxyglucose / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000378:metabolism; D006710:Homocysteine / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology; D008875:Middle Aged
D001786:Blood Glucose; D018946:Chemokine CCL5; D003847:Deoxyglucose; D006442:Glycated Hemoglobin; D006710:Homocysteine; C483024:CCL5 protein, human; C517652:hemoglobin A1c protein, human; C006584:1,5-anhydroglucitol
1; 5-anhydro-D-glucitol; RANTES; postprandial hyperglycaemia; type 2 diabetes